Cardiology | Antiarrhythmic Drug Guide | Class Ia | Disopyramide

Disopyramide

IV Dose No IV form
Oral dose < 2 yr.: 23-33 mg/kg/day (mean 30)
2-10 yr.: 9-24 mg/kg/day (mean 20)
>10 yr.: 5-13 mg/kg/day (mean 8)
divided q 6 hours, or q 12 hours for CR forms.
Maximum 1200 mg/day.
Levels 2-5 ug/ml, poorly correlated with efficacy
Kinetics Peak levels at 0.5-3 hours after oral dose. (3.4-4.0 hours after controlled release form). Nonlinear kinetics due to protein binding. Elimination half-life 5-6 hours at therapeutic levels. Large Vd in children.
Cautions Causes significant decreases in contractility! In renal failure, active metabolite (NMD) accumulates, which is even more anticholinergic than parent compound.
Interactions None with digoxin.
Atenolol decreases clearance and is synergistic in decreasing cardiac output. (Probably true for allbeta blockers).
Phenytoin increases clearance and decreases levels.
Preparations Norpace capsules: 100, 150 mg
Norpace CR: controlled release capsules: 100, 150 mg
FDA approval in children yes

Return to Antiarrhythmic Drug Guide page

© 2019 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130